Telix Pharmaceuticals (TLX) Total Current Liabilities (2023 - 2025)
Telix Pharmaceuticals (TLX) posted Total Current Liabilities of $231.6 million for Q4 2025, up 7.03% on a QoQ basis from $216.4 million in Q4 2024, and up 7.03% year-over-year from $216.4 million in Q4 2024.
Telix Pharmaceuticals (TLX) has 3 years of Total Current Liabilities data on file, last reported at $231.6 million in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 7.03% year-over-year to $231.6 million; the TTM figure through Dec 2025 stood at $231.6 million (up 7.03% YoY), while the FY2025 annual figure was $231.6 million, up 12.94% from the prior year.
- Total Current Liabilities grew to $231.6 million in Q4 2025, from $216.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $231.6 million in Q4 2025 and bottomed at $107.5 million in Q4 2023.
- A 3-year average of $185.2 million and a median of $216.4 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities soared 101.39% — and 2025, when it advanced 7.03%.
- Year by year, Total Current Liabilities stood at $107.5 million in 2023, then soared by 101.39% to $216.4 million in 2024, then gained by 7.03% to $231.6 million in 2025.
- The last three Total Current Liabilities figures came in at $231.6 million (Q4 2025), $216.4 million (Q4 2024), and $107.5 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Telix Pharmaceuticals | 4.52 Bn | 4.38 Bn | - | 231.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 231.62 Mn |
| Dec 31, 2024 | 216.40 Mn |
| Dec 31, 2023 | 107.46 Mn |